Evidence and Research

Trials have shown that daily oral PrEP works if taken correctly and consistently. But there’s still a lot to learn about new PrEP agents and how to deliver oral PrEP.


PrEP research today spans implementation research on delivering daily oral tenofovir-based PrEP and clinical trials of new agents, including vaginal ARV-containing rings and long-acting injectables. Policy and program decisions are guided by data from the original randomized clinical trials as well as newer studies. There are many moving pieces and many product types.

No single PrEP option—and no single prevention option—is right for all people, or for any one person all the time. Demonstration projects are providing information about what's available, even as research continues for additional options.

Read below to find out more about:

Clinical Trials Evidence
Open Label and Demonstration Project Evidence
Ongoing Research

News Spotlight

  • A Daily Pill Can Prevent HIV Infections. Why Don’t More People Use It?

    March 9, 2018

    There’s no question that a simple regimen of a single daily pill can slash HIV infections in people at risk. But although millions of people around the world could benefit, only 200,000 are prescribed PrEP, and 75 percent of them are in the United States. The disparity was the focus of anguished discussions this week at the largest annual US HIV/AIDS conference.

    Read more

  • Mapping PrEP: First ever data on PrEP users across the US

    March 6, 2018

    The Center for AIDS Research at Emory University's Rollins School of Public Health produces interactive online maps with visualized data on different aspects of the US HIV epidemic, and its prevention and treatment response, at AIDSVu.org. This set of maps and statistics focuses on PrEP use nationally and by state from 2012-2016.

    Read more